Clinical trial · Interventional
Mebendazole as Adjuvant Treatment for Colon Cancer
Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer
NCT03925662CI-TRIAL-00038315recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
mebendazole treating colon cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Folfox with avastin | Drug | — | UNRESOLVED |
| Mebendazole | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Folfox with avastin
- description
- Folfox with avastin only
- interventionNames
- Drug: Folfox with avastin
- type
- EXPERIMENTAL
- label
- Mebendazole
- description
- Folfox with avastin with mebendazole
- interventionNames
- Drug: Mebendazole
Primary outcomes (1)
- measure
- number of patients with tumour response
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Colorectal cancer stage 4. Exclusion Criteria: * Agranulocytosis * Pregnancy * Allergy to mebendazole.
References
Publications (1)
- DERIVEDHegazy SK, El-Azab GA, Zakaria F, Mostafa MF, El-Ghoneimy RA. Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. Life Sci. 2022 Jun 15;299:120536. doi: 10.1016/j.lfs.2022.120536. Epub 2022 Apr 3. PMID 35385794